Business context and reporting period
This summary is of Owens & Minor, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2021—not a filing identified as Accendra Health Inc. The filing describes two segments: Global Solutions, including U.S. distribution and outsourced logistics, and Global Products, which manufactures and sources medical-surgical products. Comparisons with 2020 are affected by the June 2020 divestiture of Movianto, presented as discontinued operations in 2020.
Financial performance
| Metric | Q2 2021 | Q2 2020 | First half 2021 | First half 2020 |
|---|---|---|---|---|
| Net revenue | $2,489.5 million | $1,807.7 million | $4,816.0 million | $3,930.4 million |
| Gross margin | $400.1 million; 16.07% | $269.4 million; 14.90% | $842.8 million; 17.50% | $538.0 million; 13.69% |
| Operating income | $96.9 million | $22.2 million | $243.6 million | $33.0 million |
| Net income (loss) | $65.9 million | $(55.6) million | $135.5 million | $(67.0) million |
| Diluted continuing-operations EPS | $0.87 | $0.00 | $1.80 | $(0.14) |
- Revenue increased 37.7% in Q2 and 22.5% in the first half year over year. Management cited recovery in elective procedures, higher PPE sales, elevated glove-cost pass-through, Patient Direct strength, and favorable foreign-currency translation.
- Global Solutions operating income was $18.5 million in Q2 and $27.4 million in the first half, versus losses of $10.1 million and $2.5 million, respectively, in 2020. Management attributed improvement to higher volumes and productivity and efficiency gains.
- Global Products operating income was $95.3 million in Q2 and $258.9 million in the first half, up from $51.8 million and $70.3 million. Higher PPE sales, glove-cost pass-through timing, product mix, productivity, and fixed-cost leverage helped; higher commodity and transportation costs partly offset gains.
- Q2 net income comparisons include the 2020 discontinued-operations loss of $55.8 million. For the first half, the 2021 $40.4 million debt-extinguishment loss included $15.3 million in financing-cost and fee write-offs and $25.1 million related to terminated interest-rate swaps.
Cash flow, balance sheet, and debt
- First-half operating cash flow was $12.4 million, compared with $150.5 million in 2020. Inventory growth used $298.3 million and accounts receivable growth used $57.3 million; accounts payable growth provided $127.5 million.
- First-half investing cash use was $18.7 million, including $18.7 million of capital expenditures. The prior-year period included $133.0 million of Movianto divestiture proceeds.
- Cash and cash equivalents at June 30 were $45.4 million; cash, cash equivalents, and restricted cash totaled $61.7 million. Merchandise inventory was $1.530 billion, up $296.6 million from year-end 2020.
- Total debt was $1.009 billion, including $1.008 billion of long-term debt. The company issued $500 million of 4.500% notes due 2029 and refinanced its credit arrangements in March. It reported $255 million available under its $300 million revolver and compliance with debt covenants at quarter-end.
- Net interest expense fell 46.6% in Q2 and 43.9% in the first half year over year, which management attributed primarily to lower debt and interest rates. The company estimates a 100-basis-point rate increase would reduce annual pretax earnings by approximately $2.7 million, based on quarter-end borrowings.
Outlook, risks, and unusual items
- The filing provides no specific quantitative earnings or revenue guidance. Management said the duration and full financial effects of COVID-19 remain uncertain and cautioned that elevated PPE sales, sales growth, and operational improvements may not persist. Supply-chain restrictions and costs, elective-procedure trends, and product demand remain relevant uncertainties.
- Management expects available operating cash flow and borrowing sources to fund working capital, capital expenditures, debt and lease payments, strategic growth, and other needs. Working capital is a key cash-flow sensitivity: management estimates a one-day DSO increase would affect cash or borrowing needs by approximately $27 million. Inventory days rose to 66.7 from 57.8 at year-end.
- The IRS issued proposed adjustments concerning 2015–2018 tax returns and U.S. income attributed to foreign-subsidiary product sourcing. The company disputes the IRS position and believes its reserves are adequate, but warns an adverse outcome could materially affect results, financial position, or cash flows.
- Other disclosed risks include competition and pricing pressure, customer and supplier concentration, commodity and fuel costs, foreign exchange, substantial debt and refinancing, and cyberattacks. The company added a risk factor highlighting increased cyberattack sophistication and potential operational, financial, regulatory, and reputational harm.
- Exit and realignment charges were $8.6 million in Q2 and $14.6 million in the first half of 2021, primarily related to retained Fusion5 assets, IT restructuring, and U.S. reorganization costs; management said further Fusion5-related costs may occur in 2021.
Important facts for investors to verify
- Confirm the filing issuer: the supplied 10-Q is for Owens & Minor, Inc., notwithstanding the request metadata naming Accendra Health Inc.
- Track whether PPE demand, elective-procedure recovery, glove pricing, and segment profitability continue, and how commodity and freight costs affect margins.
- Assess working-capital conversion, particularly the inventory build and sharply lower first-half operating cash flow.
- Review debt maturities, refinancing capacity, covenant headroom, variable-rate exposure, and the consequences of cross-default provisions.
- Monitor the IRS tax dispute and any changes in the company’s assessment of potential exposure.